abrdn plc acquired a new position in Veradigm Inc. (NASDAQ:MDRX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 428,580 shares of the software maker's stock, valued at approximately $4,496,000. abrdn plc owned approximately 0.39% of Veradigm as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Covestor Ltd raised its holdings in shares of Veradigm by 10.3% in the 3rd quarter. Covestor Ltd now owns 10,336 shares of the software maker's stock worth $136,000 after purchasing an additional 966 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Veradigm during the 3rd quarter worth $189,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Veradigm by 8.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,068 shares of the software maker's stock worth $264,000 after acquiring an additional 1,507 shares during the period. Orion Portfolio Solutions LLC bought a new stake in Veradigm in the 3rd quarter valued at about $313,000. Finally, AXQ Capital LP purchased a new stake in Veradigm during the third quarter valued at about $339,000.
Veradigm Stock Performance
NASDAQ MDRX traded up $0.01 on Friday, hitting $7.96. The stock had a trading volume of 249,847 shares, compared to its average volume of 578,544. The firm has a 50-day moving average of $7.75 and a 200-day moving average of $9.86. Veradigm Inc. has a 52-week low of $5.01 and a 52-week high of $14.09.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on MDRX. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $10.00 target price (down previously from $15.00) on shares of Veradigm in a research note on Tuesday, March 19th. StockNews.com assumed coverage on Veradigm in a research report on Tuesday, April 23rd. They set a "hold" rating on the stock. Barclays started coverage on Veradigm in a report on Wednesday, January 3rd. They issued an "equal weight" rating and a $11.00 price target for the company. Finally, Royal Bank of Canada decreased their price objective on Veradigm from $22.00 to $11.00 and set an "outperform" rating on the stock in a research note on Friday, January 19th. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $11.25.
Read Our Latest Report on Veradigm
Veradigm Company Profile
(
Free Report)
Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
See Also
Before you consider Veradigm, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veradigm wasn't on the list.
While Veradigm currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
